Company news

Rein Therapeutics, Inc. (NASDAQ:RNTX) news

Rein Therapeutics, Inc. news releases on 6ix. Latest, Sep 4, 2026: Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS)…

Rein Therapeutics, Inc. (NASDAQ:RNTX) news

Press releases & updates

Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress

Rein Therapeutics to Present at Upcoming September Investor Conferences

Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics : Amendment to Annual Report (Form 10-K/A)

Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis

Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF

Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Aileron Therapeutics Announces Rebranding to Rein Therapeutics

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Aileron Therapeutics to be Included in the Russell Microcap® Index

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million

Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Aileron Therapeutics Announces CEO Transition

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024

Aileron Therapeutics Announces Acquisition of Lung Therapeutics